Summary
Vertex Pharmaceuticals Incorporated filed an 8-K report on May 17, 2012, detailing the outcomes of its annual shareholder meeting held on May 16, 2012. The key events reported include shareholder approval for amendments to the company's stock and option plans, increasing the number of authorized shares for issuance. Specifically, the Amended and Restated 2006 Stock and Option Plan saw an increase of 3,000,000 shares, and the Employee Stock Purchase Plan was augmented by 2,500,000 shares. Furthermore, the meeting confirmed the election of two new directors, Jeffrey M. Leiden and Bruce I. Sachs, to the board. Shareholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the upcoming fiscal year. Notably, an advisory vote on executive compensation received mixed results, with a majority voting against the proposed program, prompting the board to commit to careful consideration of shareholder feedback.
Key Highlights
- 1Shareholders approved amendments to the Amended and Restated 2006 Stock and Option Plan, increasing authorized shares by 3,000,000.
- 2Shareholders approved amendments to the Employee Stock Purchase Plan, increasing authorized shares by 2,500,000.
- 3Jeffrey M. Leiden and Bruce I. Sachs were elected to the Board of Directors.
- 4Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2012.
- 5An advisory vote on executive compensation for named executive officers was not approved by a majority of shareholders.
- 6The company's board of directors indicated it would consider shareholder feedback on executive compensation.
- 7The filing consolidates information regarding shareholder votes from the May 16, 2012 annual meeting.